Skip to main content

Table 1 Summary of quantitative neuropathological analysis of glial fibrillary acidic protein immunohistochemistry (GFAP IHC)

From: Clinically relevant intronic splicing enhancer mutation in myelin proteolipid protein leads to progressive microglia and astrocyte activation in white and gray matter regions of the brain

Brain region C57BL/6 J PLP-ISEdel Two-way ANOVA
2mo 4mo 2mo 4mo Geno Age Inter
Cerebellum gm 100 ± 41 332 ± 83 188 ± 62 1,372 ± 457 * * *
Cerebellum wm 100 ± 17 225 ± 50 369 ± 53 740 ± 122 **** ** ns
Medulla 100 ± 30 123 ± 64 636 ± 77 1,551 ± 280 **** ** **
Pons 100 ± 53 99 ± 33 697 ± 83 2,111 ± 337 **** *** ***
Midbrain 100 ± 39 47 ± 20 396 ± 62 1,331 ± 106 **** **** ****
Thalamus 100 ± 26 107 ± 53 644 ± 173 2,031 ± 340 **** ** **
Striatum 100 ± 45 66 ± 23 87 ± 22 720 ± 163 ** ** **
Corpus callosum 100 ± 14 108 ± 19 206 ± 21 258 ± 37 **** ns ns
Cortex 100 ± 23 190 ± 39 136 ± 20 800 ± 211 ** ** *
Hippocampus 100 ± 25 137 ± 20 87 ±7 153 ± 18 ns * ns
  1. 2-month-old WT mice used as 100%. Mean ± SEM for each brain region is indicated. (n = 5 to 6 per group). Abbreviations: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; geno = genotype; gm = gray matter; inter = interaction of age and genotype; mo = month-old; ns = not significant; wm = white matter.